Glenmark Pharmaceuticals Intrinsic Value
Glenmark Pharmaceuticals (GLENMARK) median intrinsic value is ₹2072.28 from 9 valuation models (range ₹658–₹5480), vs current price ₹2192.00 — -5.5% downside (Trading Near Calculated Value), margin of safety -5.8%. Analyse GLENMARK shareholder distribution to track promoter, FII and institutional holdings.
GLENMARK Valuation Methods Summary — DCF, Graham Number & P/E
Glenmark Pharmaceuticals intrinsic value across 9 models vs current price ₹2192.00 — upside/downside and value range per method. For current market price and key ratios, visit Glenmark Pharmaceuticals share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹939.84 | ₹751.87 - ₹1127.81 | -57.1% | EPS: ₹42.72, Sector P/E: 22x |
| Book Value Method | asset | ₹5480.00 | ₹4932.00 - ₹6028.00 | +150.0% | Book Value/Share: ₹3754.29, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4384.00 | ₹3945.60 - ₹4822.40 | +100.0% | Revenue/Share: ₹5641.43, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4384.00 | ₹3945.60 - ₹4822.40 | +100.0% | EBITDA: ₹2272.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2072.28 | ₹1657.82 - ₹2486.74 | -5.5% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹657.60 | ₹591.84 - ₹723.36 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹660.02 | ₹594.02 - ₹726.02 | -69.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4384.00 | ₹3945.60 - ₹4822.40 | +100.0% | ROE: 11.5%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1899.64 | ₹1709.68 - ₹2089.60 | -13.3% | EPS: ₹42.72, BVPS: ₹3754.29 |
GLENMARK Intrinsic Value vs Market Price — All Valuation Models
Glenmark Pharmaceuticals fair value range ₹658–₹5480 vs current market price ₹2192.00 across 9 valuation models. Read GLENMARK ex-dividend dates for the complete payout history and dividend yield track record.
GLENMARK Intrinsic Value Analysis — Undervalued or Overvalued?
Glenmark Pharmaceuticals median intrinsic value ₹2072.28, current price ₹2192.00 — Trading Near Calculated Value by 5.5%, margin of safety -5.8%.
What is the intrinsic value of GLENMARK?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Glenmark Pharmaceuticals (GLENMARK) is ₹2072.28 (median value). With the current market price of ₹2192.00, this represents a -5.5% variance from our estimated fair value.
The valuation range spans from ₹657.60 to ₹5480.00, indicating ₹657.60 - ₹5480.00.
Is GLENMARK undervalued or overvalued?
Based on our multi-method analysis, Glenmark Pharmaceuticals (GLENMARK) appears to be trading near calculated value by approximately 5.5%.
GLENMARK Financial Health — Key Ratios vs Industry Benchmarks
Glenmark Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.74 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.5% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.79x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GLENMARK Cash Flow Quality — Operating & Free Cash Flow
Glenmark Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-828 Cr | ₹-828 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-265 Cr | ₹-265 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹625 Cr | ₹368 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,109 Cr | ₹951 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,131 Cr | ₹800 Cr | Positive Free Cash Flow | 8/10 |